title: Serum collagenase activity in patients with chronic liver disease.
abstract: To examine the clinical significance of serum collagenase activity in chronic liver disease, serum collagenase activity was determined in 50 patients with chronic liver disease and in 24 healthy controls. Collagenase activity was measured after reactivation by denaturing and dissociating the inhibitors with potassium thiocyanate and aminophenylmercuric acetate. In patients with chronic persistent hepatitis, serum collagenase activity was 37% lower than controls, 50% lower in those with chronic active hepatitis, 66% lower in those with cirrhosis and 68% lower in those with hepatocellular carcinoma. Serum collagenase activity was significantly and inversely correlated with serum levels of the aminoterminal propeptide of type III procollagen and type IV collagen 7S domain, indicating that serum collagenase activity decreased as liver active fibrogenesis and/or fibrosis occurred. In contrast, serum levels of the metalloproteinase inhibitor was 30% higher than controls in patients with chronic active hepatitis, 50% higher in those with cirrhosis and 80% higher in those with hepatocellular carcinoma and was inversely correlated with serum collagenase activity. These results suggest that in this assay condition serum collagenase activity is influenced by the metallo-proteinase tissue inhibitor and thus does not reflect the amount of collagenase in the fibrotic liver.
authors.affiliation: Second Department of Internal Medicine, Tottori University, School of Medicine, Yonago, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Murawaki
authors.forename: M
authors.initials: M
authors.lastname: Koda
authors.forename: S
authors.initials: S
authors.lastname: Yamada
authors.forename: H
authors.initials: H
authors.lastname: Kawasaki
authors.forename: H
authors.initials: H
authors.lastname: Shima
authors.forename: H
authors.initials: H
authors.lastname: Burkhardt
mesh_terms: D000328:Adult; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000201:enzymology / Q000473:pathology; D002908:Chronic Disease; D003094:Collagen / Q000097:blood; D017364:Collagenases / Q000097:blood*; D004591:Electrophoresis, Polyacrylamide Gel; D005260:Female; D005355:Fibrosis; D016650:Fluorescein-5-isothiocyanate; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D008099:Liver / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000097:blood / Q000201:enzymology / Q000473:pathology; D008107:Liver Diseases / Q000097:blood / Q000201:enzymology* / Q000473:pathology; D008113:Liver Neoplasms / Q000097:blood / Q000201:enzymology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood; D011347:Procollagen / Q000097:blood; D011863:Radioimmunoassay; D019714:Tissue Inhibitor of Metalloproteinases
chemical_list: D006023:Glycoproteins; D010446:Peptide Fragments; D011347:Procollagen; D019714:Tissue Inhibitor of Metalloproteinases; C041876:procollagen Type III-N-terminal peptide; D003094:Collagen; D017364:Collagenases; D016650:Fluorescein-5-isothiocyanate